• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

穆雷帕瓦定通过抑制药物外排增强环丙沙星对……的杀菌效力。 （原文中“against”后缺少具体对象）

Murepavadin Enhances the Killing Efficacy of Ciprofloxacin against by Inhibiting Drug Efflux.

作者信息

Wei Xiaoya, Zhou Dandan, Xu Congjuan, Chen Ping, Chen Shuiping, Cheng Zhihui, Jin Yongxin, Jin Shouguang, Wu Weihui

机构信息

State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, Department of Microbiology, College of Life Sciences, Nankai University, Tianjin 300071, China.

Department of Laboratory Medicine, 5th Medical Center of PLA General Hospital, Beijing 100071, China.

出版信息

Antibiotics (Basel). 2024 Aug 26;13(9):810. doi: 10.3390/antibiotics13090810.

DOI:10.3390/antibiotics13090810
PMID:39334985
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11429200/
Abstract

is a multidrug-resistant Gram-negative pathogen and one of the leading causes of ventilator-associated pneumonia and infections in patients with chronic obstructive pulmonary disease and cystic fibrosis. Murepavadin is a peptidomimetic that specifically targets outer-membrane lipopolysaccharide transport protein LptD of . In this study, we find that murepavadin enhances the bactericidal efficacy of ciprofloxacin. We further demonstrate that murepavadin increases intracellular accumulation of ciprofloxacin by suppressing drug efflux. In addition, the murepavadin-ciprofloxacin combination exhibits a synergistic bactericidal effect in an acute murine pneumonia model. In conclusion, our results identify an effective drug combination for the treatment of infections.

摘要

是一种多重耐药革兰氏阴性病原体，是呼吸机相关性肺炎以及慢性阻塞性肺疾病和囊性纤维化患者感染的主要原因之一。穆雷帕瓦定是一种拟肽，专门靶向……的外膜脂多糖转运蛋白LptD。在本研究中，我们发现穆雷帕瓦定增强了环丙沙星的杀菌效力。我们进一步证明，穆雷帕瓦定通过抑制药物外排增加了环丙沙星在细胞内的积累。此外，穆雷帕瓦定-环丙沙星组合在急性小鼠肺炎模型中表现出协同杀菌作用。总之，我们的结果确定了一种治疗……感染的有效药物组合。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/11429200/79e560354e84/antibiotics-13-00810-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/11429200/e3d56b4d47ae/antibiotics-13-00810-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/11429200/e3a712171dc5/antibiotics-13-00810-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/11429200/bf97bf516f65/antibiotics-13-00810-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/11429200/0bd6c2dbee53/antibiotics-13-00810-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/11429200/79e560354e84/antibiotics-13-00810-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/11429200/e3d56b4d47ae/antibiotics-13-00810-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/11429200/e3a712171dc5/antibiotics-13-00810-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/11429200/bf97bf516f65/antibiotics-13-00810-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/11429200/0bd6c2dbee53/antibiotics-13-00810-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b1/11429200/79e560354e84/antibiotics-13-00810-g005.jpg

相似文献

1
Murepavadin Enhances the Killing Efficacy of Ciprofloxacin against by Inhibiting Drug Efflux.穆雷帕瓦定通过抑制药物外排增强环丙沙星对……的杀菌效力。 （原文中“against”后缺少具体对象）
Antibiotics (Basel). 2024 Aug 26;13(9):810. doi: 10.3390/antibiotics13090810.
2
Murepavadin induces envelope stress response and enhances the killing efficacies of β-lactam antibiotics by impairing the outer membrane integrity of .穆雷帕维丹诱导包膜应激反应，并通过破坏（细菌）外膜完整性来增强β-内酰胺类抗生素的杀菌效力。
Microbiol Spectr. 2023 Sep 5;11(5):e0125723. doi: 10.1128/spectrum.01257-23.
3
Murepavadin promotes the killing efficacies of aminoglycoside antibiotics against by enhancing membrane potential.Murepavadin 通过增强膜电位提高氨基糖苷类抗生素对 的杀伤效力。
Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0153923. doi: 10.1128/aac.01539-23. Epub 2024 Mar 12.
4
Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane.黏菌素通过靶向细胞质膜中的脂多糖杀死细菌。
Elife. 2021 Apr 6;10:e65836. doi: 10.7554/eLife.65836.
5
Murepavadin antimicrobial activity against and resistance development in cystic fibrosis Pseudomonas aeruginosa isolates.米卡芬净对囊性纤维化铜绿假单胞菌分离株的抗菌活性和耐药性发展。
J Antimicrob Chemother. 2021 Mar 12;76(4):984-992. doi: 10.1093/jac/dkaa529.
6
Mutations in genes , , and impair the susceptibility of cystic fibrosis strains of to murepavadin.基因突变 、 和 会降低囊性纤维化菌株对 murepavadin 的敏感性。
Antimicrob Agents Chemother. 2024 Jan 10;68(1):e0129823. doi: 10.1128/aac.01298-23. Epub 2023 Dec 11.
7
Murepavadin: a new antibiotic class in the pipeline.美罗培南：研发管线中的新型抗生素类别。
Expert Rev Anti Infect Ther. 2018 Apr;16(4):259-268. doi: 10.1080/14787210.2018.1441024. Epub 2018 Feb 21.
8
Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa.抗当代（2016-17 年）广泛耐药铜绿假单胞菌临床分离株的美罗培南活性检测。
J Antimicrob Chemother. 2018 Sep 1;73(9):2400-2404. doi: 10.1093/jac/dky227.
9
Susceptibility of Pseudomonas aeruginosa Recovered from Cystic Fibrosis Patients to Murepavadin and 13 Comparator Antibiotics.从囊性纤维化患者中分离出的铜绿假单胞菌对美罗培南和 13 种对照抗生素的敏感性。
Antimicrob Agents Chemother. 2020 Jan 27;64(2). doi: 10.1128/AAC.01541-19.
10
Pharmacokinetics and Pharmacodynamics of Murepavadin in Neutropenic Mouse Models.在中性粒细胞减少症小鼠模型中，莫奈拉韦的药代动力学和药效学。
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.01699-18. Print 2019 Mar.

本文引用的文献

1
Ciprofloxacin-Loaded Inhalable Formulations against Lower Respiratory Tract Infections: Challenges, Recent Advances, and Future Perspectives.用于治疗下呼吸道感染的载环丙沙星可吸入制剂：挑战、最新进展与未来展望
Pharmaceutics. 2024 May 11;16(5):648. doi: 10.3390/pharmaceutics16050648.
2
Synthesis of the Antimicrobial Peptide Murepavadin Using Novel Coupling Agents.使用新型偶联剂合成抗菌肽 Murepavadin。
Biomolecules. 2024 Apr 27;14(5):526. doi: 10.3390/biom14050526.
3
Murepavadin promotes the killing efficacies of aminoglycoside antibiotics against by enhancing membrane potential.
Murepavadin 通过增强膜电位提高氨基糖苷类抗生素对 的杀伤效力。
Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0153923. doi: 10.1128/aac.01539-23. Epub 2024 Mar 12.
4
: Infections and novel approaches to treatment "Knowing the enemy" the threat of and exploring novel approaches to treatment.感染与新型治疗方法：“了解敌人”——感染的威胁及探索新型治疗方法
Infect Med (Beijing). 2023 May 26;2(3):178-194. doi: 10.1016/j.imj.2023.05.003. eCollection 2023 Sep.
5
Overview of Antibiotic-Induced Nephrotoxicity.抗生素诱导的肾毒性概述
Kidney Int Rep. 2023 Aug 25;8(11):2211-2225. doi: 10.1016/j.ekir.2023.08.031. eCollection 2023 Nov.
6
Murepavadin induces envelope stress response and enhances the killing efficacies of β-lactam antibiotics by impairing the outer membrane integrity of .穆雷帕维丹诱导包膜应激反应，并通过破坏（细菌）外膜完整性来增强β-内酰胺类抗生素的杀菌效力。
Microbiol Spectr. 2023 Sep 5;11(5):e0125723. doi: 10.1128/spectrum.01257-23.
7
Counteracting antibiotic resistance enzymes and efflux pumps.拮抗抗生素耐药酶和外排泵。
Curr Opin Microbiol. 2023 Oct;75:102334. doi: 10.1016/j.mib.2023.102334. Epub 2023 Jun 15.
8
Antibiotics in the clinical pipeline as of December 2022.截至 2022 年 12 月处于临床研发管线中的抗生素。
J Antibiot (Tokyo). 2023 Aug;76(8):431-473. doi: 10.1038/s41429-023-00629-8. Epub 2023 Jun 8.
9
Current and Emerging Inhaled Antibiotics for Chronic Pulmonary and Infections in Cystic Fibrosis.用于囊性纤维化慢性肺部感染的当前及新出现的吸入性抗生素
Antibiotics (Basel). 2023 Feb 28;12(3):484. doi: 10.3390/antibiotics12030484.
10
How to Use Nebulized Antibiotics in Severe Respiratory Infections.如何在严重呼吸道感染中使用雾化抗生素
Antibiotics (Basel). 2023 Jan 28;12(2):267. doi: 10.3390/antibiotics12020267.